An investigation on behalf of investors of Amarin Corporation plc (NASDAQ: AMRN) shares over potential securities laws violations by Amarin Corporation plc and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) concerning whether a series of statements by Amarin Corporation plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Ireland based Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Amarin Corporation plc reported that its annual Total Revenue rose from $130.08 million in 2016 to $181.1 million in 2017 and that its Net Loss declined from $86.35 million in 2016 to $67.86 million in 2017.

Shares of Amarin Corporation plc (NASDAQ: AMRN) reached as high as $23.14 per share on November 5, 2018.

On November 12, 2018, an article was published, entitled 'Amarin's REDUCE-IT Trial: Something Fishy?' The article addressed Amarin's 'recent revelations of positive topline results' from its REDUCE-IT trial for Vascepa, its sole product. Specifically, the article raised the possibility that 'the placebo group received an active agent that in effect was an anti-statin', and that the REDUCE-IT trial results may have consequently exaggerated the efficacy of Vascepa.